Evidence map›Paper›PMID 26860463›Full record

Observational studyAnnals of clinical microbiology and antimicrobials2016

Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study.

Mesut Yilmaz, Nazif Elaldi, İlker İnanç Balkan, Ferhat Arslan, Ayşe Alga Batırel, Mustafa Zahir Bakıcı, Mustafa Gokhan Gozel, Sevil Alkan, Aygül Doğan Çelik, Meltem Arzu Yetkin and 12 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Annals of clinical microbiology and antimicrobials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  6. Impact of a standardized management protocol and antimicrobial stewardship intervention on mortality and quality of care in Staphylococcus aureus bacteremia: a before-after study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Infectious diseases (London, England) · 2023
    Article
  16. Emerging Challenges inAdvances in medicine · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 1 country.

Mesut YilmazDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Medipol University, TEM Avrupa Otoyolu Göztepe Çıkışı No: 1, Bağcılar, 34214, İstanbul, Turkey. myilmaz@medipol.edu.tr.
Nazif ElaldiDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey. nelaldi61@yahoo.com.
İlker İnanç BalkanDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey. ilkerinancbalkan@hotmail.com.
Ferhat ArslanDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Medipol University, TEM Avrupa Otoyolu Göztepe Çıkışı No: 1, Bağcılar, 34214, İstanbul, Turkey. farslan@medipol.edu.tr.
Ayşe Alga BatırelDepartment of Infectious Diseases and Clinical Microbiology, Dr. Lütfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey. aysebatirel@yahoo.com.
Mustafa Zahir BakıcıDepartment of Medical Microbiology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey. zbakici@cumhuriyet.edu.tr.
Mustafa Gokhan GozelDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey. mggozel@cumhuriyet.edu.tr.
Sevil AlkanDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Trakya University, Edirne, Turkey. s-ewil@hotmail.com.
Aygül Doğan ÇelikDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Trakya University, Edirne, Turkey. adogancelik@yahoo.com.tr.
Meltem Arzu YetkinDepartment of Infectious Diseases and Clinical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey. arzumyetkin@yahoo.com.
Hürrem BodurDepartment of Infectious Diseases and Clinical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey. hurrembodur@gmail.com.
Melda SınırtaşDepartment of Medical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey. melda@uludag.edu.tr.
Halis AkalınDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey. halisakalin@gmail.com.
Fatma Aybala AltayDepartment of Infectious Diseases and Clinical Microbiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey. aybalaaltay@hotmail.com.
İrfan ŞencanDepartment of Infectious Diseases and Clinical Microbiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey. isencanibu@yahoo.com.
Emel AzakDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. emelazak@mynet.com.
Sibel GündeşDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. sgundes@yahoo.com.
Bahadır CeylanDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Medipol University, TEM Avrupa Otoyolu Göztepe Çıkışı No: 1, Bağcılar, 34214, İstanbul, Turkey. bceylan@medipol.edu.tr.
Recep ÖztürkDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey. drrozturk@gmail.com.
Hakan LeblebiciogluDepartment of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University, Samsun, Turkey. hakanomu@omu.edu.tr.
Haluk VahabogluDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Medeniyet University, Istanbul, Turkey. vahabo@hotmail.com.
Ali MertDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Medipol University, TEM Avrupa Otoyolu Göztepe Çıkışı No: 1, Bağcılar, 34214, İstanbul, Turkey. alimert@medipol.edu.tr.
Istanbul Medipol University · TRSivas Cumhuriyet Üniversitesi · TRAnkara Numune Eğitim ve Araştırma Hastanesi · TRBursa Uludağ Üni̇versi̇tesi̇ · TRDışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi · TRIstanbul University · TRKocaeli Üniversitesi · TRTrakya University · TRDr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi · TRIstanbul Medeniyet University · TROndokuz Mayıs University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStaphylococcus aureus is one of the causes of both community and healthcare-associated bacteremia. The attributable mortality of S. aureus bacteremia (SAB) is still higher and predictors for mortality and clinical outcomes of this condition are need to be clarified. In this prospective observational study, we aimed to examine the predictive factors for mortality in patients with SAB in eight Turkish tertiary care hospitals.

methodsAdult patients with signs and symptoms of bacteremia with positive blood cultures for S. aureus were included. All data for episodes of SAB including demographics, clinical and laboratory findings, antibiotics, and outcome were recorded for a 3-year (2010-2012) period. Cox proportional hazard model with forward selection was used to assess the independent effect of risk factors on mortality. A 28-day mortality was the dependent variable in the Cox regression analysis.

resultsA total of 255 episodes of SAB were enrolled. The median age of the patients was 59 years. Fifty-five percent of the episodes were considered as primary SAB and vascular catheter was the source of 42.1 %. Healthcare associated SAB was defined in 55.7 %. Blood cultures yielded methicillin-resistant S. aureus (MRSA) as a cause of SAB in 39.2 %. Initial empirical therapy was inappropriate in 28.2 %. Although overall mortality was observed in 52 (20.4 %), 28-day mortality rate was 15.3 %. Both the numbers of initial inappropriate empirical antibiotic treatment and the median hours to start an appropriate antibiotic between the cases of fatal outcome and survivors after fever onset were found to be similar (12/39 vs 60/216 and 6 vs 12 h, respectively; p > 0.05). High Charlson comorbidity index (CCI) score (p = 0.002), MRSA (p = 0.017), intensive care unit (ICU) admission (p < 0.001) and prior exposure to antibiotics (p = 0.002) all were significantly associated with mortality. The Cox analysis defined age [Hazard Ratio (HR) 1.03; p = 0.023], ICU admission (HR 6.9; p = 0.002), and high CCI score (HR 1.32; p = 0.002) as the independent predictive factors mortality.

conclusionsThe results of this prospective study showed that age, ICU stay and high CCI score of a patient were the independent predictors of mortality and MRSA was also significantly associated with mortality in SAB.

Indexed as

AgedAged, 80 and overAnti-Bacterial AgentsBacteremiaFemaleHumansIntensive Care UnitsMaleMiddle AgedProspective StudiesStaphylococcal InfectionsStaphylococcus aureusTurkeyAnti-Bacterial Agents

Identifiers

PMID26860463
PMCPMC4748515
OpenAlexW2259018399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.